Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials